1-6 of 6
Authors: Erik Uhlmann
Journal Article
LTBK-01. PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii1, https://doi.org/10.1093/neuonc/noae165.1301
Published: 11 November 2024
Journal Article
BIOM-28. PROGNOSTIC BIOMARKERS IN GLIOBLASTOMA PATIENTS TREATED WITH TEMOZOLOMIDE
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v10, https://doi.org/10.1093/neuonc/noad179.0039
Published: 10 November 2023
Journal Article
EXTH-57. THE IGF-2 SIGNALING PATHWAY IS A PROMISING MENINGIOMA TREATMENT TARGET
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v237, https://doi.org/10.1093/neuonc/noad179.0910
Published: 10 November 2023
Journal Article
EPCO-06. THE EPIGENETIC CIRCUIT OF HOXDERNA LONG NON-CODING RNA (LNCRNA) ACTIVATES GLIOBLASTOMA-SPECIFIC TRANSCRIPTION PROGRAMS AND SUPER-ENHANCERS GENOME-WIDE, SHAPING GLIAL CELL FATE AND TRANSFORMATION
Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Pages v124–v125, https://doi.org/10.1093/neuonc/noad179.0471
Published: 10 November 2023
Journal Article
CTIM-18. PHASE 2 STUDY OF PD-1 BLOCKADE WITH PEMBROLIZUMAB PLUS RE-IRRADIATION FOR RECURRENT GLIOBLASTOMA (RGBM) (NCT03661723)
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii63–vii64, https://doi.org/10.1093/neuonc/noac209.250
Published: 14 November 2022
Journal Article
ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Pages vi10–vi11, https://doi.org/10.1093/neuonc/noy148.036
Published: 05 November 2018
